Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer: phase 3 SPARTAN study final results.
Read here: https://meetinglibrary.asco.org/record/187437/abstract
Advertisement